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ABSTRACT
Rapid advances in nanotechnology necessitate assessment of the safety of nanomaterials
in the resulting products and applications. One key nanomaterial attracting much interest in many
areas of science and technology is graphene. Graphene is a one atom thick carbon allotrope
arranged in a two-dimensional honeycomb lattice. In addition to being extremely thin, graphene
has several extraordinary physical properties such as its exceptional mechanical strength, thermal
stability, and high electrical conductivity. Graphene itself is relatively chemically inert and
therefore pristine graphene must undergo a process called functionalization, which is
combination of chemical and physical treatments that change the properties of graphene, to make
it chemically active. Functionalization of graphene is of crucial importance as the end application
of graphene depends on proper functionalization. In the field of medicine, graphene is currently a
nanomaterial of high interest for building biosensors, DNA transistors, and probes for cancer
detection. Despite the promising applications of graphene in several areas of biomedicine, there
have been only few studies in recent years that focus on evaluating cytotoxicity of graphene on
cells, and almost no studies that investigate how graphene exposure affects cellular genetic
material. Therefore, in this study we used a novel approach to evaluate the genotoxicity, i.e., the
effects of graphene on DNA, using Escherichia coli as a prokaryotic model organism.
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INTRODUCTION
Graphene is a one-atom-thick planar sheet consisting of sp2 carbon atoms that are
densely packed in a honeycomb crystal lattice. Graphene has many unique properties such as
high surface area, high electrical conductivity, high thermal conductivity and high optical
transmittance. Due to these unique chemical and structural properties, graphene has been
attracting interest in several commercial fields. Specifically, in the field of medicine, graphene is
currently a nanomaterial of interest for building biosensors, DNA transistor and even biosensor
for cancer detection (Sun et al. 2008; Park et al. 2009; Shao et al. 2010; Feng and Liu 2011;
Kuila et al. 2012; Wang et al. 2012; Chung et al. 2013; Liu et al. 2013; Chabot et al. 2014).
Even though scientists had theorized graphene since the 1980s it was produced and
isolated in the lab for the first time in 2004. Andre Geim and Konstantin Novoselov, at the
University of Manchester were the first ones to isolate pristine graphene from graphite and their
contribution towards the isolation and characterization of graphene (Novoselov et al. 2005) won
them the Nobel Prize in Physics in 2010. Pristine graphene, which is composed of only sp2
carbon atoms, is a zero-gap semiconductor which is why it is chemically inert and needs to be
functionalized in order for graphene to have the desired chemical and physical attributes to be
used in the development of graphene based devices.
Functionalization of graphene is one of the key topics in graphene research (Georgakilas
et al. 2012, Kulia et al. 2012; Chabot et al. 2014). Generally, there are two main categories of
functionalization: chemical and nonchemical. Chemical functionalization is carried out through
the formation of new covalent bonds between the atoms native to graphene and different
functional groups (such as -O, –COOH, and -OH). In contrast, nonchemical functionalization is

1

mainly based on non-covalent interaction between functional molecules and graphene. Both
types of functionalization change the properties of pristine graphene, but the chemical routes are
more effective (Hu and Sun 2008). However, the addition of certain chemical groups to graphene
has been shown to cause oxidative stress and toxicity in bacterial cells (Akhavan 2010; Sanchez
2011; Yue et al. 2012; Yang et al. 2013). Hence, characterization of the bioactivity of various
graphene derivatives is very important so that we can develop graphene based materials and
devices that have minimum risk of toxicity to living organisms and also so that these materials
can be disposed and degraded effectively without causing any alteration to the ecological balance
(Bussy et al. 2012).
Since its discovery and successful isolation, technology for the use of graphene and its
derivatives is being developed actively (Chung et al. 2013). Due to its excellent properties, there
is a growing interest in use of graphene based nanomaterials in biomedical devices. This means
that the interaction of graphene with human cells and other living cells will increase with the
increased use of this nanomaterial. This is the very reason which is driving the study of its
biological activity as well. It is necessary to evaluate environmental risks of graphene-containing
technological objects to biological systems (Akhaven 2010; Bussy et al. 2012). Studies so far
have evaluated the effects of graphene on living cells, most importantly its effect on cell viability
and proliferation. Graphene toxicity studies show that its number of layers, lateral size, stiffness,
hydrophobicity, surface functionalization, and dose are important factors that determine its
effects on cells (Adams and Jia 2005, Georgakilas et al. 2012, Katz and Hershberg 2013, Keseler
et al. 2013). However, the toxicity and biocompatibility of graphene are debated (Bianco 2013).
Evaluating the activity of graphene against bacteria is an important first step to understanding
graphene’s bioactivity. Prokaryotic model organisms provide the basis for understanding of
2

toxicity mechanisms of graphene on a simpler scale due to their relatively simple physiological
manifestation (Efremova et al. 2015).
In 2010, Akhavan and Ghaderi first described the toxic effect of graphene against several
bacterial species and also showed that graphene oxide (produced through functionalization
process) was more toxic to cells when compared to pristine graphene. Since then, the toxicity of
different forms of graphene against bacteria has been studied extensively, but the results in these
studies are somewhat contradictory. Most studies have used some form of functionalized
graphene and compared the effects of functionalized graphene to the effects of pristine graphene
on cells. In addition to the research on properties of functionalized graphene, there have been
several studies that have linked the toxicity of graphene based materials on the presence of rough
edges of graphene which cause physical damage to cells (Liu 2011).
There have also been several studies that have looked at the interactions between
graphene based nanoparticles and human tissues and cells. Most specifically, these studies have
focused on the uptake and cellular response of macrophages to graphene nanoparticles and
histopathological response to deposition of these nanoparticles (Liao et al. 2011; Bussy et al.
2012). All studies that have been published so far have focused only on the cytotoxic effects of
graphene.
Previous unpublished work in our lab has characterized the cytotoxicity of oxidized
graphene to Escherichia coli cells and the data suggests that concentrations greater than 160
µg/ml of the functionalized graphene (FG) is toxic to E. coli. Cultures that were exposed to
commercial graphene (CG), i.e., pristine graphene, at these concentrations, however, did not
show decreases in cell density. This work served as the foundation for genotoxic analyses
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described here as the graphene concentrations used in the present study were based on the above
cytotoxicity analyses.
Since there are no studies to date that investigate the effects of graphene on the DNA of
cells we devised a novel approach to do so. The first step in this study was to evaluate the
mutagenic potential of graphene by using Fluctuation Assay. Fluctuation Assay, also known as a
Luria-Delbruck experiment, was first proposed and demonstrated by Nobel laureates Max
Delbrück and Salvador Luria in 1943 (Luria and Delbrück, 1943). This assay was developed to
assess the random nature of mutations that arise in a population of cells in the absence of any
selection pressure. For these experiments, small numbers of cells are used to inoculate several
parallel cultures (C) of bacteria that are grown to saturation in a non-selective growth medium.
Several dilutions are then plated onto selective media (e.g. antibiotic containing media) to get an
estimate of the number of mutants in each culture (r). Based on the number of mutants that grow
on selective media, mutation rates can be estimated using several mathematical equations
(described in the Results and Discussion chapter). Mutation rates are more reliable than merely
calculating the frequency of mutants as mutation frequency varies greatly between the parallel
cultures. This is because mutations are random in nature and the mutations that arise in earlier
generations will be more prevalent than the mutations arising in later generations. To normalize
for this variation, it is important to calculate mutation rate. The methods we have used for
mutation rate calculation are based on either mean or median mutation frequency (see Results
and Discussion section).
Next, we assessed the nature of mutations that graphene exposure causes to the E. coli
cells by sequencing the whole genome of representative rifampicin resistant mutants isolated in
the Fluctuation Assay (Katz and Hershberg 2013). Mutations are changes in the DNA
4

sequencing that are inherited through generations. If a mutation causes an alteration in the amino
acid sequence of protein then it is termed as nonsynonymous substitution and if the mutation
does not produce any change in the protein sequence then these changes are called synonymous
mutations. We used the Illumina MiSeq platform for sequencing the genomic DNA of these
mutants. MiSeq is a next-generation sequencing platform which produces reliable
highthroughput data (Quail et al. 2012). Paired-end reads produced from a MiSeq sequencer
were assembled to get the genome sequence of the mutants and parent, which were subsequently
used to analyze the patterns of mutations. Preprocessing of the DNA sequence data was
performed on Galaxy server (https://usegalaxy.org/) and the assemblies were generated and
analyzed using software package DNASTAR (DNA Star Inc.). We then used EcoCyc and
UniProt to understand the function of the genes that were affected by the mutations in the
genome of the mutants.
Lastly, we conducted growth analysis of the mutants (Davison et al. 2007, Wehrli 1983)
to evaluate if the mutations confer any physiological advantage to E. coli cells for growth in
presence of graphene.
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MATERIALS AND METHODS

Media and Culture Conditions
The Escherichia coli strain used in this study is DH5 alpha [F- Φ80lacZΔM15
Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, mk+) phoA supE44 λ-thi-1 gyrA96 relA1].
The E. coli DH5 cells were revived from glycerol stocks by scraping off some cells from the
frozen glycerol stock and streaking them on Luria-Bertani agar plate followed by incubating the
plate at 37C for 12 hours. The liquid media used for culturing E. coli DH5 cells in this study is
Luria-Bertani broth (Sezonov et al. 2007), which is a rich medium for E. coli growth. The
composition of Luria-Bertani media per liter is 10.0 g Tryptone, 5.0 g Yeast extract, 5.0 g
Sodium chloride. While performing Fluctuation Assay, Luria-Bertani broth was supplemented
with 100 g/ml of Rifampicin. Rifampicin stock was prepared using the protocol suggested by
Sambrook et al. (2012). Solid media used in the study was Luria-Bertani agar (Luria-Bertani
broth + 10.0 g/L agar). Luria-Bertani agar was also supplemented with 100 g/ml Rifampicin,
where appropriate.

Graphene Source and Properties
Graphene used in this study was provided by the Arkansas Research Alliance. From the
dry graphene stock received, 2 mg each of either commercial (pristine) graphene (CG) or
functionalized graphene (FG) were weighed and were resuspended in 1 ml double autoclaved
water to make stock solutions of concentration 2 mg/ml. Final concentration of commercial and
functionalized graphene used in the Fluctuation Assay experiments was 80 g/ml, so 120 l of
the stock graphene solution was added to each 3 ml liquid culture.
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Fluctuation Assay
We used Fluctuation Assay (Rosche and Foster, 2000) to estimate the frequencies of
rifampicin resistance in E. coli DH5 cells in order to estimate the spontaneous mutation rates in
E. coli DH5 cells. Fluctuation Assay was performed in two rounds using either shaken or
unshaken cultures of E. coli. In the first round, we used ten parallel, shaken cultures of E. coli
DH5 to estimate the intrinsic spontaneous mutation rate in the absence of any exposure to
graphene. Briefly, ten each 14 ml culture tubes containing 5 ml Luria-Bertani broth were
inoculated with ~1000 E. coli DH5 cells from a common starter culture. These ten parallel E.
coli DH5 cultures were then incubated overnight at 37C with 250 rpm shaking. After
incubation, 1 ml of culture was taken in a cuvette to measure the OD600 value using a
spectrophotometer to quantitate the cell density of each culture. Out of the remaining 4 ml of
culture, 100 l was spread directly on LB-agar plates containing Rifampicin, and 1 ml was
concentrated 10-fold before being spread on LB-agar plates containing Rifampicin. For
concentrating the cultures, 1 ml was taken from each of the ten culture tubes in ten 1.5 ml
microcentrifuge tubes and centrifuged at 10,000 rpm at 23C for 10 minutes. 900 μl of
supernatant was decanted from the microcentrifuge tube and the cell pellet was resuspended in
the remaining 100 l broth in the tube by vortexing. These 10-fold concentrated cultures (100 l
in volume) were spread on LB-agar plates containing Rifampicin. All 20 plates from this
experiment were incubated at 37C for 36 hours before counting the number of colony forming
units (CFUs) on each plate.
In the second round of Fluctuation Assay, we set up 5 parallel, non-shaken cultures each
for three different treatments. Fewer parallel cultures were used because the amount of graphene
received was limited, and cultures were not shaken in order to minimize the shearing effects on
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cells caused by graphene (Liu 2011). Cells were grown in 3 ml of either LB broth alone
(control), LB broth containing 80 g/ml of commercial graphene (CG), or LB broth containing
80 g/ml of functionalized graphene (FG). Five 14 ml culture tubes (per treatment) were
inoculated with ~1000 E. coli cells from a common starter culture. The cultures were incubated
for 14 hours at 37°C without shaking. After incubation, 100 l was spread directly on LB-agar
plates containing Rifampicin, and also 1 ml from the culture was concentrated 10-fold before
being spread on LB-agar plates containing Rifampicin. We spread three dilutions (10-5, 10-6, 107

) of the cultures on LB-agar plates to obtain an estimate of total viable cells per culture. We

incubated these plates at 37°C for 12-36 hours.
After 12 hours of incubation, CFUs on the LB agar plates were counted to estimate the
total number of viable cells per culture. After 36 hours of incubation, CFUs on the Rifampicin
supplemented LB agar plates were counted to estimate the total number of Rifampicin resistant
mutants.

Mutation Frequency and Mutation Rate calculation
Frequency of spontaneous mutations to Rifampicin resistance was estimated based on the
second round of Fluctuation Assay by comparing the number of mutant colonies that grew on
Rifampicin supplemented plates against the total number of cells in the culture (estimated based
on the OD600 values). For estimating the mutation rate we used three independent methods
described previously (Roshe and Foster, 2000), namely the Luria-Delbrück’s Method of the
Mean (Luria and Delbrück 1943), the Lea-Coulson’s Method of the Median (Lea and Coulson
1949) and, the Drake Formula using the median (Drake 19991).
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Genomic DNA Isolation
We isolated genomic DNA (gDNA) from six representative rifampicin resistant E. coli
mutants and the parent strain (WT) for sequencing using the Illumina MiSeq platform. Procedure
for DNA isolation is described below.
After growth on Rifampicin supplemented LB agar plates we randomly picked six
individual colonies from independent plates for sequencing. Only one colony was picked from
any given plate, and each colony originated from a different sample within each treatment.
Genomic DNA extraction of each of these mutants was performed using Qiagen DNeasy Blood
and Tissue Kit. Selected colonies were grown overnight in 5 ml LB broth supplemented with
Rifampicin at 37°C with shaking at 250 rpm. The bacterial cells were then harvested by
centrifuging the cultures for 10 minutes at 7500 rpm, supernatant was discarded and cell pellet
was resuspended in 180 l enzymatic lysis buffer and incubated at 37C for 1 hour. The
composition of the lysis buffer was 20 mM Tris-HCl, 2 mM Na-EDTA, 1.2% Triton X-100, and
20 mg/ml of lysozyme from chicken egg white (Sigma-Aldrich). After 1 hour of incubation, 180
l buffer ATL was added to the cell lyaste followed by addition of 20 l of proteinase K and
then the tubes were incubated at 56°C for 30 minutes to ensure complete lysis of the bacterial
cells. Following cell lysis, the tubes were briefly vortexed and 200 l of buffer AL was added to
the samples and the samples were vortexed briefly. Then, 200 l of 99% ethanol was added to
the samples followed by brief vortexing. The mixture was carefully transferred to DNeasy Mini
spin column and centrifuged at 8000 rpm for 1 minute after which the flow-through was
discarded. Buffer AW1 (500 l) was added to the column and the column was then centrifuged
at 8000 rpm for 1 minute following with the flow-through was discarded along with the
collection tube. Spin column was placed in a new collection tube and 500 l of buffer AW2 was
9

added to the column. The column was centrifuged at 14,000 rpm for 3 minutes for the DNeasy
membrane to dry. Flow-through was discarded along with the collection tube and the DNeasy
Mini spin column was placed in a clean 1.5 ml Eppendorf tube and 50 l of pre-warmed Qiagen
elution buffer water was added directly to the DNeasy membrane. The column was incubated for
3 minutes at room temperature and then we centrifuged the column at 8000 rpm to elute the
DNA. We repeated the elution step one more time by transferring the column to a clean 1.5 ml
Eppendorf tube and adding 50 l of pre-warmed Qiagen elution buffer, incubating the column
for 3 minute at room temperature, and then centrifuging the column at 8000 rpm to elute the
DNA.
For extraction of genomic DNA from E. coli DH5, the protocol described above was
used with some minor modification; we used RNase treatment in the protocol since the initial
gDNA preparations were contaminated with ribosomal RNA. We added 4 l of RNase A (100
mg/ml) to the cell lysate and the microcentrifuge tube was incubated at room temperature for 2
minutes which was followed by the addition of buffer AL (neutralization buffer) and ethanol.
The DNA extraction steps following the RNase treatment were the same as described above.

Genomic DNA Quantitation
We used NanoDrop (Thermo Scientific) and Qubit assay (Thermo Fisher) to evaluate the
quality of our genomic DNA samples and also to estimate the concentration of genomic DNA.
For quantifying the genomic DNA, we used Qubit dsDNA BroadRange Assay kit (Life
Technologies Inc). For each sample quantified, we diluted the assay reagent 200x in the buffer
solution provided in assay kit. We also prepared Standards 1 and 2 from the assay kit to calibrate
the Qubit fluorometer before quantifying the samples. As per manufacturer's protocol, 10 l each
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of standard 1 and standard 2 were mixed with 190 l of diluted reagent in two Qubit assay tubes,
followed by brief vortexing and centrifugation of these standard solutions. We then mixed 1 l
of the genomic DNA into 199 l of diluted reagent in Qubit assay tubes and mixed the sample by
vortexing the tubes briefly and then centrifuging the tubes briefly. The tubes were then incubated
for 1 minute at room temperature before placing the tubes in Qubit fluorometer to get the
concentration values of the sample. We used the ‘calculate stock concentration’ option on the
fluorometer to get the total concentration of the sample. We used NanoDrop to get Abs260/Abs280
ratio of the samples so we could be sure that the samples were free of contamination from
proteins. In doing so, we used 1l from each of the sample and measured its absorbance using
NanoDrop.

Agarose Gel Electrophoresis
We separated 1 l of each of the rifampicin mutant genomic DNA samples and 5 l of E.
coli DH5 genomic DNA sample on an agarose gel to check the quality of extracted genomic
DNA. Agarose gel (1% concentration) was prepared by dissolving 0.5 g agarose in 50 ml 0.5X
TBE buffer by heating in a microwave for 1 minute. The liquid agarose gel was then allowed to
cool for 5 minutes before adding 5 l SYBR Safe DNA gel stain and the liquid agarose gel was
poured in gel tray with the well comb in place and was left for 30 minutes for solidifying. After
30 minutes, the well comb was removed and the gel was transferred to electrophoresis chamber
filled with 0.5X TBE and samples were loaded in gel wells. We ran the gel at 80V for 90
minutes. DNA imaging protocol for SYBR safe (ThermoFisher Scientific) was used on a BioRad Molecular Imager Gel Doc (Bio-Rad) to visualize DNA.
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Genome Sequencing
After checking the quality and quantity of purified genomic DNA from the six
Rifampicin resistant mutants (3 mutants from commercial graphene (CG) treatment and 3
mutants from functionalized graphene (FG) treatment) and the E. coli DH5 genomic DNA, we
provided approx. 250 ng of genomic DNA of each sample to the UAMS DNA Sequencing Core
Facility for shotgun whole genome sequencing. The gDNA samples were sequenced on Illumina
MiSeq platform. DNA samples from the six mutants were bar coded and pooled together prior to
being run on a single MiSeq cartridge. A total of 23,346,132 paired-end reads (2 x 250 bp) were
obtained for the six pooled mutant genomes, and 33,857,684 paired-end reads (2 x 250 bp) were
obtained for E. coli DH5 gDNA, which was sequenced separately to obtain a higher coverage
reference sequence.

Sequence Data Preprocessing
The Fastq sequence read files obtained from the sequencing facility were uploaded on
Galaxy server (https://usegalaxy.org/). Fastq files were first groomed using FASTQ groomer
package followed by trimming of low quality reads using FASTQ quality trimmer package.
Sequences with a quality score less than 30 were trimmed from 5’ and 3’ ends using sliding
window (Window size 1, Step size 1), as well as reads with zero length were excluded from the
files. Quality of filtered and trimmed reads was assessed through FASTQC and the sequence
read files were then downloaded for subsequent analyses.
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Genome Sequence Analysis
After downloading the filtered and trimmed read files, the two files containing the left
and right paired-end sequences were concatenated in one file. After this step, we had 7 files, one
each for the six mutants and one for the parent strain. The genome of E. coli strain K-12
MG1655 was downloaded from NCBI and was used as template for assembly of all seven
genomes. The reads were first assembled using SeqMan NGen software (DNAStar, Inc.) using
the Templated Assembly Workflow using E. coli strain K-12 MG1655 as template. High SNP
Filter stringency was used while assembling the reads.
For each assembly generated through SeqMan NGen, SNP reports were created using
SeqMan Pro. SNPs were filtered using High SNP Filter stringency (%SNP >= 75% and coverage
depth >= 40). After filtering out the ambiguous SNPs, the remaining SNPs were confirmed and
exported as tab delimited files. We compared the nucleotide changes between the parent strain
(WT) and the rifampicin resistant mutants. Downstream analyses of these SNPs were done
manually by comparing the position of nucleotide change in reference sequence and nucleotide
change occurring at each position in the mutants. We used EcoCyc (Keseler et al.) and UniProt
(UniProt Consortium 2015) to find the SNP containing genes and to find the pathways that these
genes are involved in.

Growth Analysis of Mutants
We performed growth analysis (Davison et al. 2007, Wehrli 1983) of the rifampicin
resistant mutants that were isolated from Fluctuation Assay performed in the presence of
graphene in the growth medium. For doing so, we revived glycerol stocks of two CG and two FG
mutants on LB-agar plates containing rifampicin (100 µg/ml). We used the parent E. coli DH5α
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as the control (wildtype, WT) for this experiment which was revived on LB-agar plates. We then
picked a single colony from each plate and inoculated starter culture. For wildtype E. coli DH5α
we used 2 ml LB as growth medium, whereas 2 ml LB broth supplemented with rifampicin (100
µg/ml) was used for growth of CG and FG mutants. All culture tubes were incubated for 12
hours at 37°C with 250 rpm shaking. OD600 for each culture was measured for each culture after
incubation. The cell density for each culture was estimated. Approximately 106 cells from each
culture of the mutants and wildtype E. coli DH5α were used to inoculate LB broth
(supplemented with rifampicin for CG and FG mutants) in a 96-well plate. Commercial graphene
(CG) or functionalized graphene (FG) was added at concentrations 0 µg/ml (control), 80 µg/ml,
or 320 µg/ml. The 96-well plate was then incubated at 37°C for 6 hours. Following incubation,
dilution plates were made for each treatment using LB broth as medium with seven successive
10-fold dilutions. From these dilution plates, 10-3, 10-4, 10-5, 10-6, and 10-7 dilutions were plated
on LB agar plates and the plates were incubated at 37°C for 14 hours before counting the number
of colony forming units (CFUs) on each plate in order to estimate the number of viable cells in
each treatment.
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RESULTS AND DISCUSSION

Frequency of spontaneous mutations to rifampicin resistance in E. coli
To estimate the intrinsic rate of spontaneous mutations to rifampicin resistance in E. coli
DH5α cells we set up Fluctuation Assay (Rosche and Foster 2000) with 10 parallel, shaken
cultures. Cultures were grown in LB broth for 12 hours. Cell density was measured using OD600
and cell count was estimated using an online calculator
(http://www.genomics.agilent.com/biocalculators/calcODBacterial.jsp). A complete list of OD600
values and the corresponding cell densities is given in Table I. As seen from the data, the OD600
values ranged from 1.099, which corresponds to about 8.79x108 cells/ml, to 1.237, which
corresponds to about 9.9x108 cells/ml.
To determine the frequency of spontaneous mutations to rifampicin resistance (RifR),
aliquots from each culture were plated on LB-agar plates supplemented with rifampicin. The
numbers of RifR colonies per culture are given in Table II. From this experiment we estimated
that the frequency of spontaneous mutations to rifampicin resistance (RifR) in our Fluctuation
Assay cultures was about 4.76 (± 2.71 standard deviations) mutants per 108 cells. Frequency of
spontaneous mutations to rifampicin resistance has been previously reported to be 2.6 x10-8 in E.
coli strain K12 MG1655 (Katz and Hershberg, 2013) which is comparable to the mutation
frequency we observe in our experiment. The RifR frequency we determined through this
preliminary experiment helped us plan the following experiment as the RifR frequency was
neither too high nor too low for a 5 ml culture volume to be used in our subsequent Fluctuation
Assay.
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Effect of graphene exposure on the rate of spontaneous mutations to rifampicin resistance
in E. coli
In order to estimate the rate of spontaneous mutations to rifampicin resistance in E. coli
cells upon exposure to graphene, we performed the Fluctuation Assay with five parallel cultures
containing either commercial graphene (CG) or functionalized graphene (FG) or no graphene
(control). Table III lists the number of colonies formed on each plate and the cell number
calculated based on the number of colony forming units (CFUs) on plates. We estimated cell
numbers in each culture by counting the colonies on LB agar plate as we could not measure the
OD600 for cultures containing graphene. We could not rely on OD600 values for these cultures as
graphene particles in media would interfere with measurement of the optical density of cultures.
We excluded the cultures where no colonies grew on rifampicin plates from these analyses
(indicated as No Data (ND) in Table IV). We estimated average cell number in the cultures
grown in LB broth, LB broth containing commercial graphene, and LB broth containing
functionalized graphene. The cultures that were grown in the presence of graphene (either
commercial or functionalized) on average have 5 times less cells than the cultures grown in LB
broth without graphene. The cell number in the previous experiment (Fluctuation Assay in the
absence of graphene) was higher than in this experiment as the culture growth conditions
(shaking vs. non-shaking, respectively) were different between the two experiments. Cultures
tubes were incubated without shaking to prevent any potential physical damage to cells by the
rough edges of graphene (Liu 2011).
From this experiment, we estimated the frequency of RifR mutations (Table IV). The RifR
frequency was found to be around 3.98 mutants per 108 cells in the control (LB alone). The
commercial graphene (CG) and functionalized graphene (FG) treatment had RifR frequencies of
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3.93 and 8.74 per 108 cells, respectively. These data indicate an increase in the frequency of RifR
mutants in cultures exposed to functionalized graphene. The value of RifR in CG treatment is
comparable to that of LB alone (control). On the other hand, in FG treatment, the RifR frequency
is 2-fold higher than that of control (LB alone) or CG treatments.
After determining the frequency of RifR mutations, we wanted to calculate the mutation
rate under each treatment. For calculating the mutation rate for each treatment (LB control, CG,
and FG) we used three methods; the Luria- Delbrück (Luria and Delbrück 1943) method of the
mean (r=m ln(mC)), the Lea-Coulson (Lea and Coulson 1949) method of the median ((r/m) –
ln(m) = 1.24), and the Drake (Drake 19991) formula ((r/m) – ln(m) = 0). In these equations, r is
the observed number of mutants in a culture, C is the number of cultures in the experiment, and
m is the number of mutants per culture. The values for mutation rates calculated using these
methods are given in Table V. As the data suggests, all three methods give us a different value
for the mutation rate but if we compare the three mutation rates values for each treatment we see
that there is an increase in the mutation rate in cultures exposed to functionalized graphene. The
mutation rate values for CG treatment was higher than the untreated control (LB) when LuriaDelbrück method of the mean was used to calculate mutation rate, but lower when we used the
methods of median (Lea-Coulson and Drake formula). This could be due to the fact that data was
available for only three CG-treated cultures (see Table IV), which may have skewed the
calculation of the mean. Mutation rate values for FG treatment were higher than for either
control (LB alone) or CG treatment regardless of the mutation rate calculation method used. The
increased mutation rate values for FG treatment suggests that functionalized graphene is
genotoxic to E. coli.
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Whole genome sequencing and analysis of E. coli mutants and parent (WT)
After determining the mutation rates for cells grown in the presence of graphene, we
wanted to investigate the nature of mutations in the genomic DNA of mutants obtained in the
presence of CG or FG treatment. For this, we sequenced the genomic DNA of random RifR
mutants. We picked a total of six RifR mutant colonies, three each from CG and FG treatments.
These mutants were grown overnight in LB broth supplemented with Rifampicin and genomic
DNA was extracted using Qiagen DNeasy blood and tissue kit. To assess the quality of the
samples, 1 µL from each genomic DNA sample was run on agarose gel (Figure 1). For
comparing the size of extracted genomic DNA, we ran all samples against 1 kb ladder from NEB
with a range of 10,000 bp-500 bp. All samples ran as a single band >10,000 kb without any
smear or accessory band which indicates that the extracted genomic DNA was of high quality.
We then quantitated the samples using Qubit BR DNA assay and NanoDrop. Concentration and
Abs260/Abs280 ratios for each sample is given in Table VI. Values of Abs260/Abs280 ratio of
between 1.8-2.0 are indicative of pure DNA that is free of protein contamination. Approximately
250 ng from each sample was then sent for sequencing on Illumina MiSeq at UAMS DNA
sequencing facility.
We also sequenced the parent strain in order to get more reliable insight on the changes in
DNA that may have been caused by graphene exposure. We extracted genomic DNA from
parent (WT) cells and sent approx. 250 ng to UAMS DNA sequencing facility for Illumina
MiSeq sequencing. Qubit concentration and Abs260/Abs280 ratio obtained from Nanodrop for the
WT sample are given in Table VI. Figure 2 is the agarose gel image of the 5 µL of genomic
DNA ran against 1 kb ladder. The WT gDNA ran as single band >10,000 kb which confirms the
quality of DNA extracted. For sequencing we used DNA from first elution as labeled in Figure 2.
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Sequence reads that we acquired were first processed on Galaxy server
(https://usegalaxy.org/) and after filtering out the low quality reads we imported the sequence
reads in DNASTAR software (DNAStar, Inc.). A summary of reads from Illumina MiSeq
NextGen sequencing is shown in Table VII. The paired-end reads for each mutant sample were
aligned to the reference E. coli genome K-12 MG1655 and the reads assembled into a single
contig of 4,639,675 bp without gaps which is the same length as the reference genome. The
length of each contig with gaps along with the median coverage values for each contig is listed in
Table VIII. All assembled contigs had N50 value of 4641k.
Sequence reads of the genomic DNA of the parent strain (WT) were also processed and
assembled in the exact same way. Table VII lists the number of reads for the sample and the
number of low quality reads that were filtered out using the Galaxy server. The number of reads
and coverage for the parent strain were substantially higher than those of the mutants as the six
mutant samples were multiplexed whereas the parent strain was not. The median coverage and
contig length for parent strain are listed in Table VIII.
We used SeqManPro in the DNASTAR software to generate SNP reports for each of the
seven assembled genomes (parent and six mutants). From the SNP reports generated we
identified SNPs using very high stringency parameters, namely read depth of 40 or higher and
%SNP of 75% or higher. SNPs with low coverage score were rejected from further analysis.
Numbers of SNPs for each genome are given in Table IX and the number of shared/unique SNPs
is represented in a Venn diagram in Figure 3. A total of 22 mutations were common across all six
mutant genomes. In addition to the shared mutations, there are changes that are exclusive to
either CG or FG mutants which are shown in Figure 4. There are two mutations that are shared
within the three CG mutants and one mutation that is shared within the three FG mutants.
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Among the 22 mutations shared by all six mutants, 6 mutations were synonymous
(Henaut and Danchin 1996), i.e. these mutations do not cause changes in the amino acid
sequence of the protein, 6 mutations were found in non-coding portions of the genome, 3 of these
mutations occurred in the rRNA gene sequences. The non-synonymous mutations (Henaut and
Danchin 1996) were found in genes insB (insertion element), lacZ (part of lac operon which
hydrolyses lactose to galactose and glucose), mhpD (calalyzes conversion of 2hydroxypentadienoic acid to 4-hydroxy-2-ketopentanoic acid), ymfE (uncharacterized membrane
protein), and wbbK (putative glycosyltransferase, part of outer membrane biogenesis). We could
not find any evidence from literature on the association between these genes and bacterial stress
response.
The mutations that are not shared by all six mutants are given in Table X. The table has
information about the mutants which have the mutation, position of nucleotide change,
nucleotide base change, and the gene which has that mutation. There are 4 different nonsynonymous mutations in the rpoB gene. Mutations in rpoB gene are known to confer resistance
to Rifampicin (Reynolds 2000). Gene yghO also contains a non-synonymous mutation and this
gene is involved in biofilm production (Beloin et al. 2004). The other two non-synonymous
changes are present in the promoter regions of genes fixA and yhhW. Gene fixA is predicted to
play a role in electron transport in E. coli (Eichler et al. 1995) and gene yhhW is proposed to be
involved in a mechanism that prevents inhibition of DNA gyrase by quercetin (Adams and Jia
2005). None of these genes, however, have previously been shown to be directly involved in
pathways related to stress response in E. coli.
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Functional characterization of genomic mutations induced by graphene exposure
We performed growth analysis (Davison et al. 2007, Wehrli 1983) of the FG and CG
mutants from Fluctuation Assay to assess whether mutations towards rifampicin confers any
selective advantage to these mutants when compared to wildtype E. coli DH5α cells. We picked
two CG and two FG mutants (which we had already sequenced) for this test and included
wildtype E. coli DH5α cells as control. Each strain was revived from frozen glycerol stocks on
LB agar plates and then grown in liquid medium to be used in the experiment. CG and FG
mutants were grown in medium supplemented with rifampicin and the wildtype cells were grown
in non-selective media. OD600 values were measured and cell densities of the cultures were
estimated (Table XI) to ensure each treatment has comparable number of cells at the beginning
of experiment. The CG, FG mutants and the wildtype cells were each exposed to either
commercial or functional graphene at concentrations 0 µg/ml (control), 80 µg/ml, and 320 µg/ml.
After incubation, five dilutions (10-3, 10-4,10-5, 10-6, and 10-7) from each treatment were spread
on LB agar plates to estimate the number of viable cells in each culture.
Plates where 10-3 and 10-4 dilutions were plated had a lawn of bacteria in each treatment,
and therefore it was not possible to get a cell count from these dilutions. Table XII contains the
cell count for all the other dilutions. Mutant FG1 dilution plates had lawns even on the 10-5, 10-6,
and 10-7 dilutions and hence that data has been marked as TNTC (too many to count) in the table.
Based on the number of colony forming units on each plate, we calculated the average number of
viable cells. The average cell density for CG1 and CG2 mutants, FG2 mutant, and WT E. coli
DH5α cells is represented in Figure 5 along with the standard error bars.
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Since these mutants were originally obtained upon exposure of E. coli to commercial or
functionalized graphene at concentration 80 µg/ml, we expected that CG mutants will have
higher viability when re-exposed to commercial graphene at this concentration and FG mutants
will have higher viability when re-exposed to 80 µg/ml of functionalized graphene.
Results from the CG mutants did not show a consistent trend. CG2 grew better in the
presence of either commercial or functionalized graphene compared to the control. CG1 grew
slightly better in the presence of commercial and functionalized graphene compared to control,
except at 80 µg/ml of functionalized graphene. FG2 also showed better growth in the presence of
commercial graphene, but not in the presence of functionalized graphene, compared to the
control. From previous work in our lab, we know that functionalized graphene is cytotoxic to
WT E. coli DH5α cells. Data from the WT cultures are in general agreement with our previous
data. However, data obtained for WT exposed to 320 µg/ml of functionalized graphene was
surprising and may represent an error in data acquisition in this study. Additional experiments
are needed to clarify if the mutations isolated from graphene exposure confer any physiological
advantage to E. coli.
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CONCLUSION
This study used a novel approach to study the genotoxic effects of graphene on the E. coli
genome. By performing Fluctuation Assay we calculated and compared the rate of mutation to
rifampicin resistance (RifR) in the presence and absence of graphene. From this experiment we
concluded that there is an increase in RifR mutation rate when cells are exposed to functionalized
graphene. We then selected and sequenced the genomes six RifR mutants from Fluctuation Assay
to analyze mutations in the genomes of the mutants. Using very high stringency parameters, we
discovered 25-27 nucleotide changes in the genomes of the mutants when compared to the parent
out of which 22 changes were shared by all mutants. This was very interesting as these mutants
came from different plates, samples, and treatments. If mutations were truly random we would
not have seen the same position and nucleotide change in all six mutants. Finally, since the
mutations arose in the presence of either commercial or functionalized graphene, we wanted to
test if the mutants had any growth advantage in the presence of either graphene. Results from
this experiment revealed that in general, all mutants grew better in the presence of commercial
graphene compared to the control, while only the CG mutants grew better in the presence of
functionalized graphene compared to control. Additional experiments are needed to understand
the physiological relevance of these mutations in E. coli.
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Tables and Figures
Table I
OD600 and cell density values for ten untreated, shaken cultures of E. coli used for Fluctuation
Assay
Culture number

OD600 values after 12 hours

Estimated cell density (per ml)

1

1.099

8.79 x108

2

1.156

9.25 x108

3

1.133

9.06 x108

4

1.195

9.56 x108

5

1.131

9.05 x108

6

1.115

8.92 x108

7

1.14

9.12 x108

8

1.129

9.03 x108

9

1.237

9.9 x108

10

1.158

9.26 x108

28

Table II
Calculation of the frequency of spontaneous mutations to rifampicin resistance (RifR) in
untreated, shaken cultures of E. coli

Culture
number

Number of
colonies on
Rif plates
(100 μl)

Number of
colonies on
Rif plates
(100 μl) x10

Number of
colonies on
Rif plates
(1ml)

Average
number of
RifR
mutants

Estimated
cell
density
(per ml)

RifR
frequency
per 108
cells

1

3

30

127

78.5

8.79 x108

8.93

2

1

10

61

35.5

9.25 x108

3.84

3

2

20

26

23

9.06 x108

2.54

4

1

10

18

14

9.56 x108

1.46

5

1

10

22

16

9.05 x108

1.77

6

2

20

73

46.5

8.92 x108

5.21

7

3

30

93

61.5

9.12 x108

6.74

8

2

20

49

34.5

9.03 x108

3.82

9

ND

ND

43

43

9.9 x108

4.34

10

ND

ND

83

83

9.26 x108

8.96

Average RifR mutation frequency per 108 cells

4.76

Standard deviation

2.71

Note: ND (no data) indicates that no colonies grew on the corresponding plate.
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Table III
Cell density values for five treated, non-shaken cultures of E. coli used for Fluctuation Assay
Culture
number

Number of colonies
on LB-agar plates
(10-5 dilution)

Number of colonies
on LB-agar plates
(10-6 dilution)

Number of colonies
on LB-agar plates
(10-7 dilution)

Cell density
per culture

LB1

TNTC

215

23

2.23 x108

LB2

TNTC

153

37

2.62 x108

LB3

TNTC

197

35

2.74 x108

LB4

TNTC

235

36

2.98 x108

LB5

TNTC

328

96

6.44 x108
3.40 x108

Average cell density for LB cultures
CG1

612

48

2

0.43 x108

CG2

564

54

7

0.60 x108

CG3

572

53

8

0.63 x108

CG4

556

63

2

0.46 x108

CG5

456

57

4

0.48 x108
0.52 x108

Average cell density for CG-treated cultures
FG1

656

50

7

0.62 x108

FG2

560

72

3

0.53 x108

FG3

724

62

6

0.65 x108

FG4

372

59

9

0.62 x108

FG5

592

59

11

0.76 x108
0.63 x108

Average cell density for FG-treated cultures

Note: TNTC (too many to count) indicates that there was a bacterial lawn on the corresponding
plate. LB indicates control (untreated) cultures; CG indicates CG-treated cultures; FG indicates
FG-treated cultures of E. coli.

30

Table IV
Calculation of the frequency of spontaneous mutations to rifampicin resistance (RifR) in treated,
non-shaken cultures of E. coli
Average
number of
RifR mutants

RifR
frequency per
108 cell

9

9.5

4.27

20

19

19.5

7.46

ND

ND

3

3

1.10

LB4

ND

ND

4

4

1.34

LB5

4

40

34

37

5.75

Culture
number

Number of
colonies on Rif
plates (100μl)

Number of
colonies on Rif
plates (100μl)
x10

Number of
colonies on Rif
plates (1ml)

LB1

1

10

LB2

2

LB3

Average RifR mutation frequency for LB cultures

3.98

CG1

ND

ND

ND

ND

ND

CG2

ND

ND

3

3

2.78

CG3

ND

ND

ND

ND

ND

CG4

ND

ND

2

2

3.12

CG5

ND

ND

4

4

5.89

Average RifR mutation frequency for CG-treated cultures

3.93

FG1

ND

ND

1

1

0.87

FG2

ND

ND

2

2

2.41

FG3

2

20

6

13

10.32

FG4

1

10

7

8.5

7.35

FG5

5

50

29

39.5

22.76

Average RifR mutation frequency for FG-treated cultures

8.74

Note: ND, no data was available as no colonies grew on the corresponding plate. LB indicates
control (untreated) cultures; CG indicates CG-treated cultures; FG indicates FG-treated cultures
of E. coli.
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Table V
Calculation of the rate of spontaneous mutations to rifampicin resistance in treated, non-shaken
cultures of E. coli
Treatment

LD mean

LC median

Drake formula

Control (LB alone)

1.807

2.122

3.164

CG exposure

2.134

1.737

3.097

FG exposure

3.448

2.915

4.729
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Table VI
Concentration and Abs260/Abs280 ratio of genomic DNA extracted from RifR mutants and parent
(WT)
Sample

Concentration (ng/µl)

A260/A280 ratio

CG1

72.8

1.80

CG2

72.2

1.82

CG3

61.6

1.96

FG4

98.6

1.77

FG5

40.2

1.78

FG6

52.2

1.99

WT

44.2

1.97
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Table VII
Summary of reads from Illumina MiSeq NextGen sequencing of the E. coli genomic DNA
Sample

Total reads
obtained

Low-quality reads
(filtered out)

Final number of high-quality reads used for
genome assembly

CG1

4,754,534

1,444

4,753,090

CG2

3,445,746

771

3,444,975

CG3

4,564,014

2,658

4,561,356

FG4

4,239,402

1,120

4,238,282

FG5

3,504,652

622

3,504,030

FG6

2,837,784

2,705

2,835,079

WT

33,857,684

27,893

33,829,791
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Table VIII
Summary of genome assembly statistics using DNASTAR software
Sample

Contig length with gaps

Median coverage

CG1

4,640,974

213.30

CG2

4,640,676

166.28

CG3

4,641,042

200.99

FG4

4,641,046

203.28

FG5

4,640,972

175.00

FG6

4,640,599

136.92

WT

4,645,702

1411
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Table IX
Number of nucleotide mutations in each genome

Sample

Number of
nucleotide
mutations

CG1

25

CG2

27

CG3

27

FG4

25

FG5

27

FG6

27
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Table X
Summary of nucleotide mutations not shared by all mutants
Mutant

Nucleotide

Nucleotide change

Gene or region

fixA promoter

position
CG1,CG2,CG3,FG4,FG5

42108

A>G

CG3,FG5,FG6

2302544

GG>TC

FG6

3128183

G>A

yghO

CG2

3205570

G>-

ttdB

FG4,FG5,FG6

3579873

A>G

yhhw promoter

CG2,CG3

3742392

T>C

yiaM

FG5

3939897

C>T

rRNA

CG1,CG2,CG3,FG5,FG6

4169804

G>A

rRNA

CG1,FG6

4179710

A>C

rpoB

CG2,CG3

4180852

C>T

rpoB

FG5

4180954

A>C

rpoB

FG4

4180981

A>C

rpoB
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Table XI
OD600 values of the cultures of E. coli mutants used for growth analysis
Sample
CG1
CG2
FG1
FG2
WT

OD600
1.327
1.355
0.813
1.196
1.456

Cell density
1.06 x109
1.08 x109
6.5 x108
9.57 x108
1.16 x109
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Table XII
Number of colony forming units (CFUs) on dilution plates for growth analysis
Sample

CG1

Graphene
conc.
(µg/ml)
0
80
320

Commercial Graphene
10
10-6
10-7
dilution
dilution
dilution
67
46
6
880
59
4
368
69
6
-5

Functionalized graphene
10-5
10-6
10-7
dilution
dilution
dilution
624
24
6
528
53
1
444
100
7

CG2

0
80
320

376
724
784

48
81
114

8
9
7

336
788
534

52
52
81

7
8
11

FG1

0
80
320

TNTC

TNTC

TNTC

TNTC

TNTC

TNTC

FG2

0
80
320

178
556
508

24
61
33

4
4
5

406
894
702

55
94
90

11
7
8

WT

0
80
320

250
430
328

58
57
40

3
3
8

212
228
296

26
35
44

4
1
5

Note: TNTC (too many to count) indicates that there was a bacterial lawn on the corresponding
plate.

39

Figure 1
Agarose gel electrophoresis of genomic DNA isolated from CG and FG mutants for genome
sequencing
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Figure 2
Agarose gel electrophoresis of genomic DNA isolated from E. coli DH5α for genome
sequencing
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Figure 3
Analysis of shared and unique mutations in the genomes of CG and FG mutants

FG6
5

CG1
3

FG5
5

CG2
5

22

CG3
5

FG4
3

42

Figure 4
Analysis of shared and unique mutations within the genomes of either CG or FG mutants
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FG5
4

Figure 5
Effect of graphene on the growth of CG and FG mutants as well as parent (WT)
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